Review of treatment strategies after lymphadenectomy: From molecular therapeutics to immediate microsurgical lymphatic reconstruction

ObjectiveLymphedema is a common complication of cancer treatment such as lymphadenectomy and radiation therapy. It is a debilitating condition with pathologic tissue changes that hinder effective curative treatment and jeopardize patients’ quality of life. Various attempts to prevent the development of lymphedema have been made with improvements in the incidence of the pathology. However, it is still prevalent among cancer survivors. In this paper, we review both molecular therapeutics and immediate surgical lymphatic reconstruction as treatment strategies after lymphadenectomy. Specifically, we discuss pro-lymphangiogenic molecules that have proved efficacy in animal models of lymphedema and clinical trials, and review currently available microsurgical techniques of immediate lymphatic reconstruction.MethodsA literature search was conducted in PubMed, Embase, Cochrane library, and Google Scholar through May 2022. Searches were done separately for molecular therapeutics and microsurgical techniques for immediate lymphatic reconstruction. Search terms used for (1) non-surgical methods include ‘lymphangiogenesis’, ‘lymphedema’, ‘growth factor’, and ‘gene therapy’. Search terms used for (2) surgical methods include ‘lymphedema’, ‘lymph node excision’, ‘lymphatic vessels’, ‘primary prevention’, and ‘microsurgery’.ResultsVarious pro-lymphangiogenic factors with therapeutic potential include VEGF-C, VEGF-D, HGF, bFGF, PDGF, IGF, Retinoic acid, Ang-1, S1P, TLR4, and IL-8. Microsurgical lymphatic reconstruction for prevention of secondary lymphedema includes lymphovenous anastomosis (LYMPHA), vascularized lymph node flap transfer, and lymph-interpositional flap transfer (LIFT), with promising clinical outcomes.ConclusionsWith growing knowledge of the lymphangiogenic pathway and lymphedema pathology and advances in microsurgical techniques to restore lymphatic channels, molecular and surgical approaches may represent a promising method for primary prevention of lymphedema. Lymphedema is a common complication of cancer treatment such as lymphadenectomy and radiation therapy. It is a debilitating condition with pathologic tissue changes that hinder effective curative treatment and jeopardize patients’ quality of life. Various attempts to prevent the development of lymphedema have been made with improvements in the incidence of the pathology. However, it is still prevalent among cancer survivors. In this paper, we review both molecular therapeutics and immediate surgical lymphatic reconstruction as treatment strategies after lymphadenectomy. Specifically, we discuss pro-lymphangiogenic molecules that have proved efficacy in animal models of lymphedema and clinical trials, and review currently available microsurgical techniques of immediate lymphatic reconstruction. A literature search was conducted in PubMed, Embase, Cochrane library, and Google Scholar through May 2022. Searches were done separately for molecular therapeutics and microsurgical techniques for immediate lymphatic reconstruction. Search terms used for (1) non-surgical methods include ‘lymphangiogenesis’, ‘lymphedema’, ‘growth factor’, and ‘gene therapy’. Search terms used for (2) surgical methods include ‘lymphedema’, ‘lymph node excision’, ‘lymphatic vessels’, ‘primary prevention’, and ‘microsurgery’. Various pro-lymphangiogenic factors with therapeutic potential include VEGF-C, VEGF-D, HGF, bFGF, PDGF, IGF, Retinoic acid, Ang-1, S1P, TLR4, and IL-8. Microsurgical lymphatic reconstruction for prevention of secondary lymphedema includes lymphovenous anastomosis (LYMPHA), vascularized lymph node flap transfer, and lymph-interpositional flap transfer (LIFT), with promising clinical outcomes. With growing knowledge of the lymphangiogenic pathway and lymphedema pathology and advances in microsurgical techniques to restore lymphatic channels, molecular and surgical approaches may represent a promising method for primary prevention of lymphedema.